Villeurbanne Faces Financial Chaos Jeopardizing Ambitious EuroLeague Plans
Villeurbanne, a prominent EuroLeague basketball club, is confronting a severe financial crisis that threatens its ambitious plans for the 2026 season. The club had initially set a staggering budget target of 59 million euros, a 40 million euro increase from the previous season, aiming to transform from a mid-tier team into a top contender. However, recent developments have cast doubt on this goal.
According to French outlet L'Equipe, Villeurbanne presented an alternative plan to French financial regulators last Wednesday, proposing a drastically reduced budget of approximately 24 million euros. This shift followed a major setback when one of the club's key financial partners failed to provide the necessary guarantees to support the large player contracts, even after the club requested additional time to resolve the issue.
In response, the club devised a backup plan to meet regulatory approval but now urgently seeks a new financial partner to help achieve its original budget. The turmoil has significant implications for player contracts, including those of Francisco (earning about 4.1 million euros per season), Armoni Brooks (around 2 million euros), Nick Weiler-Babb, and the recently signed Daniel Theis. Reports suggest that under the reduced budget plan, player salaries would total only 10 million euros, making it nearly impossible to honor existing commitments.
This financial uncertainty could force Villeurbanne into a difficult position where it cannot maintain the contracts promised to its new signings. The club's future and ability to compete at the highest EuroLeague level now hinge on resolving this financial impasse. Observers await further developments to see if Villeurbanne can navigate out of this crisis.
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.